uploads/2015/10/cphd-pm.jpg

Cepheid’s Revenue and Income Fell in 3Q15

By

Updated

Cepheid’s price movement

Cepheid (CPHD) has a market capitalization of $2.3 billion. Cepheid’s YTD (year-to-date) price movement has been falling since August 2015.

After its 3Q15 earnings report, Cepheid fell by 0.86% to close at $32.25 per share as of October 20, 2015, with a 4.8% fall in revenue in 3Q15. Its price movements on a weekly, monthly, and YTD basis are -18.6%, -37.1%, and -40.4%, respectively.

Technically, Cepheid has broken all major support and is trading below all of its moving averages. Currently, it’s trading at -24.9% below its 20-day moving average, -31.8% below its 50-day moving average, and -40.9% below its 200-day moving average.

The First Trust NYSE Arca Biotechnology ETF (FBT) invests 3.1% of its holdings in Cepheid. The ETF tracks an equal-weighted index of US biotechnology stocks. The YTD price movement of the ETF is 0.60% as of October 19, 2015.

Cepheid’s competitors and their market capitalizations are as follows:

  • Thermo Fisher Scientific (TMO) — $51.3 billion
  • Becton, Dickinson and Company (BDX) — $29.4 billion
  • Alere (ALR) — $4.0 billion
  • Bio-Rad Laboratories (BIO) — $4.0 billion

Cepheid’s 3Q15 performance

Cepheid reported net revenue of $126.5 million in 3Q15, a fall of 4.8% compared to its net revenue of $132.5 million in 2Q15. Its cost of sales as a percentage of sales rose by 1.9% in 3Q15.

The company’s net income fell to -$22.9 million in 3Q15 as compared to its net income of -$16.7 million in 2Q15. Its current and debt-to-equity ratios have increased to 3.88 and 1.23, respectively, in 3Q15 as compared to a current and debt-to-equity ratios of 3.86 and 1.20 in 2Q15.

About Cepheid

Cepheid is a molecular diagnostics company. It develops, manufactures, and markets easy-to-use molecular systems and tests.

More From Market Realist